Objective Oral direct thrombin and anti-Xa inhibitors have been shown to be efficacious in
the prevention and treatment of venous thromboembolism, and prevention of embolic events …

Aims There are concerns regarding increased risk of acute coronary syndrome with
dabigatran. We aimed to assess whether alternative treatment options such as rivaroxaban …

Dabigatran has been associated with greater risk of myocardial infarction (MI) than warfarin.
It is unknown whether the increased risk is unique to dabigatran, an adverse effect shared …

We assessed the cardiovascular safety of long-term direct-acting oral anticoagulant (DOAC)
treatment. A search of the medical literature was performed from inception until May 31 …

Dabigatran is a univalent low-molecular-weight direct thrombin inhibitor that has been
developed as an alternative to vitamin K antagonists (VKAs). However, uncertainty remains …

The relative cardiovascular (CV) safety of oral anticoagulants continues to be debated, and
in particular concerns for risk of myocardial infarction (MI) have been raised. We analyzed …

Background Despite receipt of dual antiplatelet therapy, patients after an acute coronary
syndrome (ACS) remain at significant risk for thrombotic events. The role of orally activated …

Atrial fibrillation is an increasingly common arrhythmia, now said to stand at epidemic
proportion in Western societies:. 2.3 million people in the USA and. 4.5 million people in …

Background The original RE-LY (Randomized Evaluation of Long-term Anticoagulant
Therapy) trial suggested a small increased risk of myocardial infarction (MI) with the use of …

Background A meta-analysis was performed to evaluate the risk of major bleeding with the
use of New Oral Anticoagulants (NOACs). Methods Randomized controlled trials (RCTs) …